<?xml version="1.0" encoding="UTF-8"?><TED_EXPORT xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="ted/R2.0.8.S03/publication" xmlns:n2016="ted/2016/nuts" xsi:schemaLocation="ted/R2.0.8.S03/publication TED_EXPORT.xsd" DOC_ID="070793-2018" EDITION="2018032"><TECHNICAL_SECTION><RECEPTION_ID>18-072385-001</RECEPTION_ID><DELETION_DATE>20180306</DELETION_DATE><FORM_LG_LIST>DA DE EN ES FI FR EL IT NL PT SV CS ET HU LT LV MT PL SK SL GA BG RO HR </FORM_LG_LIST><COMMENTS>From Convertor</COMMENTS></TECHNICAL_SECTION><LINKS_SECTION><XML_SCHEMA_DEFINITION_LINK xlink:type="simple" xlink:href="http://ted.europa.eu" xlink:title="TED WEBSITE"/><OFFICIAL_FORMS_LINK xlink:type="simple" xlink:href="http://ted.europa.eu"/><FORMS_LABELS_LINK xlink:type="simple" xlink:href="http://ted.europa.eu"/><ORIGINAL_CPV_LINK xlink:type="simple " xlink:href="http://ted.europa.eu"/><ORIGINAL_NUTS_LINK xlink:type="simple" xlink:href="http://ted.europa.eu"/></LINKS_SECTION><CODED_DATA_SECTION><REF_OJS><COLL_OJ>S</COLL_OJ><NO_OJ>32</NO_OJ><DATE_PUB>20180215</DATE_PUB></REF_OJS><NOTICE_DATA><NO_DOC_OJS>2018/S 032-070793</NO_DOC_OJS><URI_LIST><URI_DOC LG="DA">http://ted.europa.eu/udl?uri=TED:NOTICE:070793-2018:TEXT:DA:HTML</URI_DOC><URI_DOC LG="DE">http://ted.europa.eu/udl?uri=TED:NOTICE:070793-2018:TEXT:DE:HTML</URI_DOC><URI_DOC LG="EN">http://ted.europa.eu/udl?uri=TED:NOTICE:070793-2018:TEXT:EN:HTML</URI_DOC><URI_DOC LG="ES">http://ted.europa.eu/udl?uri=TED:NOTICE:070793-2018:TEXT:ES:HTML</URI_DOC><URI_DOC LG="FI">http://ted.europa.eu/udl?uri=TED:NOTICE:070793-2018:TEXT:FI:HTML</URI_DOC><URI_DOC LG="FR">http://ted.europa.eu/udl?uri=TED:NOTICE:070793-2018:TEXT:FR:HTML</URI_DOC><URI_DOC LG="EL">http://ted.europa.eu/udl?uri=TED:NOTICE:070793-2018:TEXT:EL:HTML</URI_DOC><URI_DOC LG="IT">http://ted.europa.eu/udl?uri=TED:NOTICE:070793-2018:TEXT:IT:HTML</URI_DOC><URI_DOC LG="NL">http://ted.europa.eu/udl?uri=TED:NOTICE:070793-2018:TEXT:NL:HTML</URI_DOC><URI_DOC LG="PT">http://ted.europa.eu/udl?uri=TED:NOTICE:070793-2018:TEXT:PT:HTML</URI_DOC><URI_DOC LG="SV">http://ted.europa.eu/udl?uri=TED:NOTICE:070793-2018:TEXT:SV:HTML</URI_DOC><URI_DOC LG="CS">http://ted.europa.eu/udl?uri=TED:NOTICE:070793-2018:TEXT:CS:HTML</URI_DOC><URI_DOC LG="ET">http://ted.europa.eu/udl?uri=TED:NOTICE:070793-2018:TEXT:ET:HTML</URI_DOC><URI_DOC LG="HU">http://ted.europa.eu/udl?uri=TED:NOTICE:070793-2018:TEXT:HU:HTML</URI_DOC><URI_DOC LG="LT">http://ted.europa.eu/udl?uri=TED:NOTICE:070793-2018:TEXT:LT:HTML</URI_DOC><URI_DOC LG="LV">http://ted.europa.eu/udl?uri=TED:NOTICE:070793-2018:TEXT:LV:HTML</URI_DOC><URI_DOC LG="MT">http://ted.europa.eu/udl?uri=TED:NOTICE:070793-2018:TEXT:MT:HTML</URI_DOC><URI_DOC LG="PL">http://ted.europa.eu/udl?uri=TED:NOTICE:070793-2018:TEXT:PL:HTML</URI_DOC><URI_DOC LG="SK">http://ted.europa.eu/udl?uri=TED:NOTICE:070793-2018:TEXT:SK:HTML</URI_DOC><URI_DOC LG="SL">http://ted.europa.eu/udl?uri=TED:NOTICE:070793-2018:TEXT:SL:HTML</URI_DOC><URI_DOC LG="GA">http://ted.europa.eu/udl?uri=TED:NOTICE:070793-2018:TEXT:GA:HTML</URI_DOC><URI_DOC LG="BG">http://ted.europa.eu/udl?uri=TED:NOTICE:070793-2018:TEXT:BG:HTML</URI_DOC><URI_DOC LG="RO">http://ted.europa.eu/udl?uri=TED:NOTICE:070793-2018:TEXT:RO:HTML</URI_DOC><URI_DOC LG="HR">http://ted.europa.eu/udl?uri=TED:NOTICE:070793-2018:TEXT:HR:HTML</URI_DOC></URI_LIST><LG_ORIG>DE</LG_ORIG><ISO_COUNTRY VALUE="DE"/><IA_URL_GENERAL/><ORIGINAL_CPV CODE="33600000">Pharmaceutical products</ORIGINAL_CPV><n2016:PERFORMANCE_NUTS CODE="DE">DEUTSCHLAND</n2016:PERFORMANCE_NUTS><REF_NOTICE><NO_DOC_OJS>2015/S 207-375270</NO_DOC_OJS></REF_NOTICE></NOTICE_DATA><CODIF_DATA><DS_DATE_DISPATCH>20180214</DS_DATE_DISPATCH><DT_DATE_FOR_SUBMISSION>20171005</DT_DATE_FOR_SUBMISSION><AA_AUTHORITY_TYPE CODE="6">Body governed by public law</AA_AUTHORITY_TYPE><TD_DOCUMENT_TYPE CODE="2">Additional information</TD_DOCUMENT_TYPE><NC_CONTRACT_NATURE CODE="2">Supplies</NC_CONTRACT_NATURE><PR_PROC CODE="1">Open procedure</PR_PROC><RP_REGULATION CODE="5">European Union, with participation by GPA countries</RP_REGULATION><TY_TYPE_BID CODE="1">Submission for all lots</TY_TYPE_BID><AC_AWARD_CRIT CODE="Z">Not specified</AC_AWARD_CRIT><MA_MAIN_ACTIVITIES CODE="B">Social protection</MA_MAIN_ACTIVITIES><MA_MAIN_ACTIVITIES CODE="H">Health</MA_MAIN_ACTIVITIES><HEADING>012EC</HEADING></CODIF_DATA></CODED_DATA_SECTION><TRANSLATION_SECTION><ML_TITLES><ML_TI_DOC LG="DA"><TI_CY>Tyskland</TI_CY><TI_TOWN>Hamburg</TI_TOWN><TI_TEXT>Lægemidler</TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="DE"><TI_CY>Deutschland</TI_CY><TI_TOWN>Hamburg</TI_TOWN><TI_TEXT>Arzneimittel</TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="EN"><TI_CY>Germany</TI_CY><TI_TOWN>Hamburg</TI_TOWN><TI_TEXT>Pharmaceutical products</TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="ES"><TI_CY>Alemania</TI_CY><TI_TOWN>Hamburgo</TI_TOWN><TI_TEXT>Productos farmacéuticos</TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="FI"><TI_CY>Saksa</TI_CY><TI_TOWN>Hampuri</TI_TOWN><TI_TEXT>Farmaseuttiset tuotteet</TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="FR"><TI_CY>Allemagne</TI_CY><TI_TOWN>Hambourg</TI_TOWN><TI_TEXT>Produits pharmaceutiques</TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="EL"><TI_CY>Γερμανία</TI_CY><TI_TOWN>Αμβούργο</TI_TOWN><TI_TEXT>Φαρμακευτικά προϊόντα</TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="IT"><TI_CY>Germania</TI_CY><TI_TOWN>Amburgo</TI_TOWN><TI_TEXT>Prodotti farmaceutici</TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="NL"><TI_CY>Duitsland</TI_CY><TI_TOWN>Hamburg</TI_TOWN><TI_TEXT>Farmaceutische producten</TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="PT"><TI_CY>Alemanha</TI_CY><TI_TOWN>Hamburgo</TI_TOWN><TI_TEXT>Produtos farmacêuticos</TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="SV"><TI_CY>Tyskland</TI_CY><TI_TOWN>Hamburg</TI_TOWN><TI_TEXT>Läkemedel</TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="CS"><TI_CY>Německo</TI_CY><TI_TOWN>Hamburk</TI_TOWN><TI_TEXT>Léčivé přípravky a zdravotnické prostředky</TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="ET"><TI_CY>Saksamaa</TI_CY><TI_TOWN>Hamburg</TI_TOWN><TI_TEXT>Ravimid</TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="HU"><TI_CY>Németország</TI_CY><TI_TOWN>Hamburg</TI_TOWN><TI_TEXT>Gyógyszerészeti termékek</TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="LT"><TI_CY>Vokietija, VFR</TI_CY><TI_TOWN>Hamburgas</TI_TOWN><TI_TEXT>Farmacijos produktai</TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="LV"><TI_CY>Vācija</TI_CY><TI_TOWN>Hamburga</TI_TOWN><TI_TEXT>Farmācijas izstrādājumi</TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="MT"><TI_CY>il-Ġermanja</TI_CY><TI_TOWN>Ħamburgu</TI_TOWN><TI_TEXT>Prodotti farmaċewtiċi</TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="PL"><TI_CY>Niemcy</TI_CY><TI_TOWN>Hamburg</TI_TOWN><TI_TEXT>Produkty farmaceutyczne</TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="SK"><TI_CY>Nemecko</TI_CY><TI_TOWN>Hamburg</TI_TOWN><TI_TEXT>Farmaceutické výrobky</TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="SL"><TI_CY>Nemčija</TI_CY><TI_TOWN>Hamburg</TI_TOWN><TI_TEXT>Farmacevtski proizvodi</TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="GA"><TI_CY>Ghearmáin, an</TI_CY><TI_TOWN>Hamburg</TI_TOWN><TI_TEXT>Pharmaceutical products</TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="BG"><TI_CY>Гepмaния</TI_CY><TI_TOWN>Хамбург</TI_TOWN><TI_TEXT>Фармацевтични продукти</TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="RO"><TI_CY>Germania</TI_CY><TI_TOWN>Hamburg</TI_TOWN><TI_TEXT>Produse farmaceutice</TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="HR"><TI_CY>Njemačka</TI_CY><TI_TOWN>Hamburg</TI_TOWN><TI_TEXT>Farmaceutski proizvodi</TI_TEXT></ML_TI_DOC></ML_TITLES><ML_AA_NAMES><AA_NAME LG="DA">DAK-Gesundheit</AA_NAME><AA_NAME LG="DE">DAK-Gesundheit</AA_NAME><AA_NAME LG="EN">DAK-Gesundheit</AA_NAME><AA_NAME LG="ES">DAK-Gesundheit</AA_NAME><AA_NAME LG="FI">DAK-Gesundheit</AA_NAME><AA_NAME LG="FR">DAK-Gesundheit</AA_NAME><AA_NAME LG="EL">DAK-Gesundheit</AA_NAME><AA_NAME LG="IT">DAK-Gesundheit</AA_NAME><AA_NAME LG="NL">DAK-Gesundheit</AA_NAME><AA_NAME LG="PT">DAK-Gesundheit</AA_NAME><AA_NAME LG="SV">DAK-Gesundheit</AA_NAME><AA_NAME LG="CS">DAK-Gesundheit</AA_NAME><AA_NAME LG="ET">DAK-Gesundheit</AA_NAME><AA_NAME LG="HU">DAK-Gesundheit</AA_NAME><AA_NAME LG="LT">DAK-Gesundheit</AA_NAME><AA_NAME LG="LV">DAK-Gesundheit</AA_NAME><AA_NAME LG="MT">DAK-Gesundheit</AA_NAME><AA_NAME LG="PL">DAK-Gesundheit</AA_NAME><AA_NAME LG="SK">DAK-Gesundheit</AA_NAME><AA_NAME LG="SL">DAK-Gesundheit</AA_NAME><AA_NAME LG="GA">DAK-Gesundheit</AA_NAME><AA_NAME LG="BG">DAK-Gesundheit</AA_NAME><AA_NAME LG="RO">DAK-Gesundheit</AA_NAME><AA_NAME LG="HR">DAK-Gesundheit</AA_NAME></ML_AA_NAMES></TRANSLATION_SECTION><FORM_SECTION><OTH_NOT CATEGORY="TRANSLATION" LG="DA" VERSION="R2.0.8.S03.E01"><FD_OTH_NOT><TI_DOC><P>DE-Hamburg: Lægemidler</P></TI_DOC><STI_DOC><P><ADDRESS_NOT_STRUCT><ORGANISATION>DAK-Gesundheit</ORGANISATION><BLK_BTX>, </BLK_BTX><ADDRESS>Nagelsweg 27-31</ADDRESS><BLK_BTX>, Att: </BLK_BTX><ATTENTION>Strategischer Einkauf und Vergabestelle II – 0042 60</ATTENTION><BLK_BTX>, </BLK_BTX><TOWN>Hamburg</TOWN><BLK_BTX> </BLK_BTX><POSTAL_CODE>20097</POSTAL_CODE><BLK_BTX>, </BLK_BTX><COUNTRY VALUE="DE"/><BLK_BTX>. Telefon: </BLK_BTX><PHONE>+49 402396-2779</PHONE><BLK_BTX>. Fax: </BLK_BTX><FAX>+49 402396-3661</FAX><BLK_BTX>. Mailadresse: </BLK_BTX><E_MAIL>vergabestelle@dak.de</E_MAIL></ADDRESS_NOT_STRUCT></P></STI_DOC><STI_DOC><P><FT TYPE="REFOJ">(Supplement til Den Europæiske Unions Tidende, 24.10.2015, 2015/S 207-375270)</FT></P></STI_DOC><OBJ_NOT><INT_OBJ_NOT>Vedr:</INT_OBJ_NOT><CPV><CPV_MAIN><CPV_CODE CODE="33600000"/></CPV_MAIN></CPV><BLK_BTX><P>Lægemidler</P></BLK_BTX></OBJ_NOT><CONTENTS><CORREC><DEL><MIXED>Uafsluttet procedure</MIXED><MIXED>Ordretildelingsproceduren er forblevet resultatløs</MIXED></DEL></CORREC><P>Yderligere supplerende oplysninger</P><P>Das Zulassungsverfahren zum Wirkstoff Estramustin, ATC L01XX11 endete zum regulären Ende zum 30.11.2017. Es erfolgte kein Vertragsbeitritt.</P></CONTENTS></FD_OTH_NOT></OTH_NOT><OTH_NOT CATEGORY="ORIGINAL" LG="DE" VERSION="R2.0.8.S03.E01"><FD_OTH_NOT><TI_DOC><P>DE-Hamburg: Arzneimittel</P></TI_DOC><STI_DOC><P><ADDRESS_NOT_STRUCT><ORGANISATION>DAK-Gesundheit</ORGANISATION><BLK_BTX>, </BLK_BTX><ADDRESS>Nagelsweg 27-31</ADDRESS><BLK_BTX>, Zu Händen von: </BLK_BTX><ATTENTION>Strategischer Einkauf und Vergabestelle II – 0042 60</ATTENTION><BLK_BTX>, </BLK_BTX><TOWN>Hamburg</TOWN><BLK_BTX> </BLK_BTX><POSTAL_CODE>20097</POSTAL_CODE><BLK_BTX>, </BLK_BTX><COUNTRY VALUE="DE"/><BLK_BTX>. Telefon: </BLK_BTX><PHONE>+49 402396-2779</PHONE><BLK_BTX>. Fax: </BLK_BTX><FAX>+49 402396-3661</FAX><BLK_BTX>. E-Mail: </BLK_BTX><E_MAIL>vergabestelle@dak.de</E_MAIL></ADDRESS_NOT_STRUCT></P></STI_DOC><STI_DOC><P><FT TYPE="REFOJ">(Supplement zum Amtsblatt der Europäischen Union, 24.10.2015, 2015/S 207-375270)</FT></P></STI_DOC><OBJ_NOT><INT_OBJ_NOT>Betr.:</INT_OBJ_NOT><CPV><CPV_MAIN><CPV_CODE CODE="33600000"/></CPV_MAIN></CPV><BLK_BTX><P>Arzneimittel</P></BLK_BTX></OBJ_NOT><CONTENTS><CORREC><DEL><MIXED>Nichtabgeschlossenes Verfahren</MIXED><MIXED>Das Vergabeverfahren war erfolglos</MIXED></DEL></CORREC><P>Weitere zusätzliche Informationen</P><P>Das Zulassungsverfahren zum Wirkstoff Estramustin, ATC L01XX11 endete zum regulären Ende zum 30.11.2017. Es erfolgte kein Vertragsbeitritt.</P></CONTENTS></FD_OTH_NOT></OTH_NOT><OTH_NOT CATEGORY="TRANSLATION" LG="EN" VERSION="R2.0.8.S03.E01"><FD_OTH_NOT><TI_DOC><P>DE-Hamburg: Pharmaceutical products</P></TI_DOC><STI_DOC><P><ADDRESS_NOT_STRUCT><ORGANISATION>DAK-Gesundheit</ORGANISATION><BLK_BTX>, </BLK_BTX><ADDRESS>Nagelsweg 27-31</ADDRESS><BLK_BTX>, For the attention of: </BLK_BTX><ATTENTION>Strategischer Einkauf und Vergabestelle II – 0042 60</ATTENTION><BLK_BTX>, </BLK_BTX><TOWN>Hamburg</TOWN><BLK_BTX> </BLK_BTX><POSTAL_CODE>20097</POSTAL_CODE><BLK_BTX>, </BLK_BTX><COUNTRY VALUE="DE"/><BLK_BTX>. Telephone: </BLK_BTX><PHONE>+49 402396-2779</PHONE><BLK_BTX>. Fax: </BLK_BTX><FAX>+49 402396-3661</FAX><BLK_BTX>. E-mail: </BLK_BTX><E_MAIL>vergabestelle@dak.de</E_MAIL></ADDRESS_NOT_STRUCT></P></STI_DOC><STI_DOC><P><FT TYPE="REFOJ">(Supplement to the Official Journal of the European Union, 24.10.2015, 2015/S 207-375270)</FT></P></STI_DOC><OBJ_NOT><INT_OBJ_NOT>Object:</INT_OBJ_NOT><CPV><CPV_MAIN><CPV_CODE CODE="33600000"/></CPV_MAIN></CPV><BLK_BTX><P>Pharmaceutical products</P></BLK_BTX></OBJ_NOT><CONTENTS><CORREC><DEL><MIXED>Incomplete procedure</MIXED><MIXED>The awarding procedure has been declared unsuccessful</MIXED></DEL></CORREC><P>Other additional information</P><P>Das Zulassungsverfahren zum Wirkstoff Estramustin, ATC L01XX11 endete zum regulären Ende zum 30.11.2017. Es erfolgte kein Vertragsbeitritt.</P></CONTENTS></FD_OTH_NOT></OTH_NOT><OTH_NOT CATEGORY="TRANSLATION" LG="ES" VERSION="R2.0.8.S03.E01"><FD_OTH_NOT><TI_DOC><P>DE-Hamburgo: Productos farmacéuticos</P></TI_DOC><STI_DOC><P><ADDRESS_NOT_STRUCT><ORGANISATION>DAK-Gesundheit</ORGANISATION><BLK_BTX>, </BLK_BTX><ADDRESS>Nagelsweg 27-31</ADDRESS><BLK_BTX>, A la atención de: </BLK_BTX><ATTENTION>Strategischer Einkauf und Vergabestelle II – 0042 60</ATTENTION><BLK_BTX>, </BLK_BTX><TOWN>Hamburg</TOWN><BLK_BTX> </BLK_BTX><POSTAL_CODE>20097</POSTAL_CODE><BLK_BTX>, </BLK_BTX><COUNTRY VALUE="DE"/><BLK_BTX>. Teléfono: </BLK_BTX><PHONE>+49 402396-2779</PHONE><BLK_BTX>. Fax: </BLK_BTX><FAX>+49 402396-3661</FAX><BLK_BTX>. Correo electrónico: </BLK_BTX><E_MAIL>vergabestelle@dak.de</E_MAIL></ADDRESS_NOT_STRUCT></P></STI_DOC><STI_DOC><P><FT TYPE="REFOJ">(Suplemento al Diario Oficial de la Unión Europea, 24.10.2015, 2015/S 207-375270)</FT></P></STI_DOC><OBJ_NOT><INT_OBJ_NOT>Objeto:</INT_OBJ_NOT><CPV><CPV_MAIN><CPV_CODE CODE="33600000"/></CPV_MAIN></CPV><BLK_BTX><P>Productos farmacéuticos</P></BLK_BTX></OBJ_NOT><CONTENTS><CORREC><DEL><MIXED>Procedimiento incompleto</MIXED><MIXED>El procedimiento de adjudicación ha sido declarado infructuoso</MIXED></DEL></CORREC><P>otras informaciones adicionales</P><P>Das Zulassungsverfahren zum Wirkstoff Estramustin, ATC L01XX11 endete zum regulären Ende zum 30.11.2017. Es erfolgte kein Vertragsbeitritt.</P></CONTENTS></FD_OTH_NOT></OTH_NOT><OTH_NOT CATEGORY="TRANSLATION" LG="FI" VERSION="R2.0.8.S03.E01"><FD_OTH_NOT><TI_DOC><P>DE-Hampuri: Farmaseuttiset tuotteet</P></TI_DOC><STI_DOC><P><ADDRESS_NOT_STRUCT><ORGANISATION>DAK-Gesundheit</ORGANISATION><BLK_BTX>, </BLK_BTX><ADDRESS>Nagelsweg 27-31</ADDRESS><BLK_BTX>, Vastaanottaja: </BLK_BTX><ATTENTION>Strategischer Einkauf und Vergabestelle II – 0042 60</ATTENTION><BLK_BTX>, </BLK_BTX><TOWN>Hamburg</TOWN><BLK_BTX> </BLK_BTX><POSTAL_CODE>20097</POSTAL_CODE><BLK_BTX>, </BLK_BTX><COUNTRY VALUE="DE"/><BLK_BTX>. Puhelin: </BLK_BTX><PHONE>+49 402396-2779</PHONE><BLK_BTX>. Faksi: </BLK_BTX><FAX>+49 402396-3661</FAX><BLK_BTX>. Sähköpostiosoite: </BLK_BTX><E_MAIL>vergabestelle@dak.de</E_MAIL></ADDRESS_NOT_STRUCT></P></STI_DOC><STI_DOC><P><FT TYPE="REFOJ">(Euroopan unionin virallisen lehden täydennysosa, 24.10.2015, 2015/S 207-375270)</FT></P></STI_DOC><OBJ_NOT><INT_OBJ_NOT>Viite:</INT_OBJ_NOT><CPV><CPV_MAIN><CPV_CODE CODE="33600000"/></CPV_MAIN></CPV><BLK_BTX><P>Farmaseuttiset tuotteet</P></BLK_BTX></OBJ_NOT><CONTENTS><CORREC><DEL><MIXED>Menettelyn keskeyttäminen</MIXED><MIXED>Hankintamenettely ei tuottanut tulosta</MIXED></DEL></CORREC><P>Muut täydentävät tiedot</P><P>Das Zulassungsverfahren zum Wirkstoff Estramustin, ATC L01XX11 endete zum regulären Ende zum 30.11.2017. Es erfolgte kein Vertragsbeitritt.</P></CONTENTS></FD_OTH_NOT></OTH_NOT><OTH_NOT CATEGORY="TRANSLATION" LG="FR" VERSION="R2.0.8.S03.E01"><FD_OTH_NOT><TI_DOC><P>DE-Hambourg: Produits pharmaceutiques</P></TI_DOC><STI_DOC><P><ADDRESS_NOT_STRUCT><ORGANISATION>DAK-Gesundheit</ORGANISATION><BLK_BTX>, </BLK_BTX><ADDRESS>Nagelsweg 27-31</ADDRESS><BLK_BTX>, À l'attention de: </BLK_BTX><ATTENTION>Strategischer Einkauf und Vergabestelle II – 0042 60</ATTENTION><BLK_BTX>, </BLK_BTX><TOWN>Hamburg</TOWN><BLK_BTX> </BLK_BTX><POSTAL_CODE>20097</POSTAL_CODE><BLK_BTX>, </BLK_BTX><COUNTRY VALUE="DE"/><BLK_BTX>. Téléphone: </BLK_BTX><PHONE>+49 402396-2779</PHONE><BLK_BTX>. Fax: </BLK_BTX><FAX>+49 402396-3661</FAX><BLK_BTX>. E-mail: </BLK_BTX><E_MAIL>vergabestelle@dak.de</E_MAIL></ADDRESS_NOT_STRUCT></P></STI_DOC><STI_DOC><P><FT TYPE="REFOJ">(Supplément au Journal officiel de l'Union européenne, 24.10.2015, 2015/S 207-375270)</FT></P></STI_DOC><OBJ_NOT><INT_OBJ_NOT>Objet:</INT_OBJ_NOT><CPV><CPV_MAIN><CPV_CODE CODE="33600000"/></CPV_MAIN></CPV><BLK_BTX><P>Produits pharmaceutiques</P></BLK_BTX></OBJ_NOT><CONTENTS><CORREC><DEL><MIXED>Procédure incomplète</MIXED><MIXED>La procédure de passation a été déclarée infructueuse</MIXED></DEL></CORREC><P>Autres informations complémentaires</P><P>Das Zulassungsverfahren zum Wirkstoff Estramustin, ATC L01XX11 endete zum regulären Ende zum 30.11.2017. Es erfolgte kein Vertragsbeitritt.</P></CONTENTS></FD_OTH_NOT></OTH_NOT><OTH_NOT CATEGORY="TRANSLATION" LG="EL" VERSION="R2.0.8.S03.E01"><FD_OTH_NOT><TI_DOC><P>DE-Αμβούργο: Φαρμακευτικά προϊόντα</P></TI_DOC><STI_DOC><P><ADDRESS_NOT_STRUCT><ORGANISATION>DAK-Gesundheit</ORGANISATION><BLK_BTX>, </BLK_BTX><ADDRESS>Nagelsweg 27-31</ADDRESS><BLK_BTX>, Υπόψη: </BLK_BTX><ATTENTION>Strategischer Einkauf und Vergabestelle II – 0042 60</ATTENTION><BLK_BTX>, </BLK_BTX><TOWN>Hamburg</TOWN><BLK_BTX> </BLK_BTX><POSTAL_CODE>20097</POSTAL_CODE><BLK_BTX>, </BLK_BTX><COUNTRY VALUE="DE"/><BLK_BTX>. Τηλέφωνο: </BLK_BTX><PHONE>+49 402396-2779</PHONE><BLK_BTX>. Φαξ: </BLK_BTX><FAX>+49 402396-3661</FAX><BLK_BTX>. Ηλεκτρονικό ταχυδρομείο: </BLK_BTX><E_MAIL>vergabestelle@dak.de</E_MAIL></ADDRESS_NOT_STRUCT></P></STI_DOC><STI_DOC><P><FT TYPE="REFOJ">(Συμπλήρωμα στην Επίσημη Εφημερίδα της Ευρωπαϊκής Ένωσης, 24.10.2015, 2015/S 207-375270)</FT></P></STI_DOC><OBJ_NOT><INT_OBJ_NOT>Θέμα:</INT_OBJ_NOT><CPV><CPV_MAIN><CPV_CODE CODE="33600000"/></CPV_MAIN></CPV><BLK_BTX><P>Φαρμακευτικά προϊόντα</P></BLK_BTX></OBJ_NOT><CONTENTS><CORREC><DEL><MIXED>Ελλιπής διαδικασία</MIXED><MIXED>Η διαδικασία ανάθεσης κρίθηκε ανεπιτυχής</MIXED></DEL></CORREC><P>Λοιπες συμπληρωματικες πληροφοριες</P><P>Das Zulassungsverfahren zum Wirkstoff Estramustin, ATC L01XX11 endete zum regulären Ende zum 30.11.2017. Es erfolgte kein Vertragsbeitritt.</P></CONTENTS></FD_OTH_NOT></OTH_NOT><OTH_NOT CATEGORY="TRANSLATION" LG="IT" VERSION="R2.0.8.S03.E01"><FD_OTH_NOT><TI_DOC><P>DE-Amburgo: Prodotti farmaceutici</P></TI_DOC><STI_DOC><P><ADDRESS_NOT_STRUCT><ORGANISATION>DAK-Gesundheit</ORGANISATION><BLK_BTX>, </BLK_BTX><ADDRESS>Nagelsweg 27-31</ADDRESS><BLK_BTX>, All'attenzione di: </BLK_BTX><ATTENTION>Strategischer Einkauf und Vergabestelle II – 0042 60</ATTENTION><BLK_BTX>, </BLK_BTX><TOWN>Hamburg</TOWN><BLK_BTX> </BLK_BTX><POSTAL_CODE>20097</POSTAL_CODE><BLK_BTX>, </BLK_BTX><COUNTRY VALUE="DE"/><BLK_BTX>. Telefono: </BLK_BTX><PHONE>+49 402396-2779</PHONE><BLK_BTX>. Fax: </BLK_BTX><FAX>+49 402396-3661</FAX><BLK_BTX>. Posta elettronica: </BLK_BTX><E_MAIL>vergabestelle@dak.de</E_MAIL></ADDRESS_NOT_STRUCT></P></STI_DOC><STI_DOC><P><FT TYPE="REFOJ">(Supplemento alla Gazzetta ufficiale dell'Unione europea, 24.10.2015, 2015/S 207-375270)</FT></P></STI_DOC><OBJ_NOT><INT_OBJ_NOT>Oggetto:</INT_OBJ_NOT><CPV><CPV_MAIN><CPV_CODE CODE="33600000"/></CPV_MAIN></CPV><BLK_BTX><P>Prodotti farmaceutici</P></BLK_BTX></OBJ_NOT><CONTENTS><CORREC><DEL><MIXED>Procedura incompleta</MIXED><MIXED>La procedura di aggiudicazione è stata dichiarata infruttuosa</MIXED></DEL></CORREC><P>Altre informazioni complementari</P><P>Das Zulassungsverfahren zum Wirkstoff Estramustin, ATC L01XX11 endete zum regulären Ende zum 30.11.2017. Es erfolgte kein Vertragsbeitritt.</P></CONTENTS></FD_OTH_NOT></OTH_NOT><OTH_NOT CATEGORY="TRANSLATION" LG="NL" VERSION="R2.0.8.S03.E01"><FD_OTH_NOT><TI_DOC><P>DE-Hamburg: Farmaceutische producten</P></TI_DOC><STI_DOC><P><ADDRESS_NOT_STRUCT><ORGANISATION>DAK-Gesundheit</ORGANISATION><BLK_BTX>, </BLK_BTX><ADDRESS>Nagelsweg 27-31</ADDRESS><BLK_BTX>, Ter attentie van: </BLK_BTX><ATTENTION>Strategischer Einkauf und Vergabestelle II – 0042 60</ATTENTION><BLK_BTX>, </BLK_BTX><TOWN>Hamburg</TOWN><BLK_BTX> </BLK_BTX><POSTAL_CODE>20097</POSTAL_CODE><BLK_BTX>, </BLK_BTX><COUNTRY VALUE="DE"/><BLK_BTX>. Telefoon: </BLK_BTX><PHONE>+49 402396-2779</PHONE><BLK_BTX>. Fax: </BLK_BTX><FAX>+49 402396-3661</FAX><BLK_BTX>. E-mail: </BLK_BTX><E_MAIL>vergabestelle@dak.de</E_MAIL></ADDRESS_NOT_STRUCT></P></STI_DOC><STI_DOC><P><FT TYPE="REFOJ">(Supplement op het Publicatieblad van de Europese Unie, 24.10.2015, 2015/S 207-375270)</FT></P></STI_DOC><OBJ_NOT><INT_OBJ_NOT>Betreft:</INT_OBJ_NOT><CPV><CPV_MAIN><CPV_CODE CODE="33600000"/></CPV_MAIN></CPV><BLK_BTX><P>Farmaceutische producten</P></BLK_BTX></OBJ_NOT><CONTENTS><CORREC><DEL><MIXED>Onvolledige procedure</MIXED><MIXED>De gunningsprocedure heeft niet tot de gewenste resultaten geleid</MIXED></DEL></CORREC><P>Overige nadere inlichtingen</P><P>Das Zulassungsverfahren zum Wirkstoff Estramustin, ATC L01XX11 endete zum regulären Ende zum 30.11.2017. Es erfolgte kein Vertragsbeitritt.</P></CONTENTS></FD_OTH_NOT></OTH_NOT><OTH_NOT CATEGORY="TRANSLATION" LG="PT" VERSION="R2.0.8.S03.E01"><FD_OTH_NOT><TI_DOC><P>DE-Hamburgo: Produtos farmacêuticos</P></TI_DOC><STI_DOC><P><ADDRESS_NOT_STRUCT><ORGANISATION>DAK-Gesundheit</ORGANISATION><BLK_BTX>, </BLK_BTX><ADDRESS>Nagelsweg 27-31</ADDRESS><BLK_BTX>, À atenção de: </BLK_BTX><ATTENTION>Strategischer Einkauf und Vergabestelle II – 0042 60</ATTENTION><BLK_BTX>, </BLK_BTX><TOWN>Hamburg</TOWN><BLK_BTX> </BLK_BTX><POSTAL_CODE>20097</POSTAL_CODE><BLK_BTX>, </BLK_BTX><COUNTRY VALUE="DE"/><BLK_BTX>. Telefone: </BLK_BTX><PHONE>+49 402396-2779</PHONE><BLK_BTX>. Fax: </BLK_BTX><FAX>+49 402396-3661</FAX><BLK_BTX>. Correio electrónico: </BLK_BTX><E_MAIL>vergabestelle@dak.de</E_MAIL></ADDRESS_NOT_STRUCT></P></STI_DOC><STI_DOC><P><FT TYPE="REFOJ">(Suplemento do Jornal Oficial da União Europeia, 24.10.2015, 2015/S 207-375270)</FT></P></STI_DOC><OBJ_NOT><INT_OBJ_NOT>Objecto:</INT_OBJ_NOT><CPV><CPV_MAIN><CPV_CODE CODE="33600000"/></CPV_MAIN></CPV><BLK_BTX><P>Produtos farmacêuticos</P></BLK_BTX></OBJ_NOT><CONTENTS><CORREC><DEL><MIXED>Concurso incompleto</MIXED><MIXED>O concurso foi declarado infrutífero</MIXED></DEL></CORREC><P>Outras informações complementares</P><P>Das Zulassungsverfahren zum Wirkstoff Estramustin, ATC L01XX11 endete zum regulären Ende zum 30.11.2017. Es erfolgte kein Vertragsbeitritt.</P></CONTENTS></FD_OTH_NOT></OTH_NOT><OTH_NOT CATEGORY="TRANSLATION" LG="SV" VERSION="R2.0.8.S03.E01"><FD_OTH_NOT><TI_DOC><P>DE-Hamburg: Läkemedel</P></TI_DOC><STI_DOC><P><ADDRESS_NOT_STRUCT><ORGANISATION>DAK-Gesundheit</ORGANISATION><BLK_BTX>, </BLK_BTX><ADDRESS>Nagelsweg 27-31</ADDRESS><BLK_BTX>, Att: </BLK_BTX><ATTENTION>Strategischer Einkauf und Vergabestelle II – 0042 60</ATTENTION><BLK_BTX>, </BLK_BTX><TOWN>Hamburg</TOWN><BLK_BTX> </BLK_BTX><POSTAL_CODE>20097</POSTAL_CODE><BLK_BTX>, </BLK_BTX><COUNTRY VALUE="DE"/><BLK_BTX>. Telefon: </BLK_BTX><PHONE>+49 402396-2779</PHONE><BLK_BTX>. Fax: </BLK_BTX><FAX>+49 402396-3661</FAX><BLK_BTX>. E-post: </BLK_BTX><E_MAIL>vergabestelle@dak.de</E_MAIL></ADDRESS_NOT_STRUCT></P></STI_DOC><STI_DOC><P><FT TYPE="REFOJ">(Tillägg till Europeiska unionens officiella tidning, 24.10.2015, 2015/S 207-375270)</FT></P></STI_DOC><OBJ_NOT><INT_OBJ_NOT>Angående:</INT_OBJ_NOT><CPV><CPV_MAIN><CPV_CODE CODE="33600000"/></CPV_MAIN></CPV><BLK_BTX><P>Läkemedel</P></BLK_BTX></OBJ_NOT><CONTENTS><CORREC><DEL><MIXED>Ofullständigt förfarande</MIXED><MIXED>Tilldelningsförfarandet har inte gett något resultat</MIXED></DEL></CORREC><P>Övriga ytterligare upplysningar</P><P>Das Zulassungsverfahren zum Wirkstoff Estramustin, ATC L01XX11 endete zum regulären Ende zum 30.11.2017. Es erfolgte kein Vertragsbeitritt.</P></CONTENTS></FD_OTH_NOT></OTH_NOT><OTH_NOT CATEGORY="TRANSLATION" LG="CS" VERSION="R2.0.8.S03.E01"><FD_OTH_NOT><TI_DOC><P>DE-Hamburk: Léčivé přípravky a zdravotnické prostředky</P></TI_DOC><STI_DOC><P><ADDRESS_NOT_STRUCT><ORGANISATION>DAK-Gesundheit</ORGANISATION><BLK_BTX>, </BLK_BTX><ADDRESS>Nagelsweg 27-31</ADDRESS><BLK_BTX>, K rukám: </BLK_BTX><ATTENTION>Strategischer Einkauf und Vergabestelle II – 0042 60</ATTENTION><BLK_BTX>, </BLK_BTX><TOWN>Hamburg</TOWN><BLK_BTX> </BLK_BTX><POSTAL_CODE>20097</POSTAL_CODE><BLK_BTX>, </BLK_BTX><COUNTRY VALUE="DE"/><BLK_BTX>. Tel.: </BLK_BTX><PHONE>+49 402396-2779</PHONE><BLK_BTX>. Fax: </BLK_BTX><FAX>+49 402396-3661</FAX><BLK_BTX>. E-mail: </BLK_BTX><E_MAIL>vergabestelle@dak.de</E_MAIL></ADDRESS_NOT_STRUCT></P></STI_DOC><STI_DOC><P><FT TYPE="REFOJ">(Dodatek k Úřednímu věstníku Evropské unie, 24.10.2015, 2015/S 207-375270)</FT></P></STI_DOC><OBJ_NOT><INT_OBJ_NOT>Předmět:</INT_OBJ_NOT><CPV><CPV_MAIN><CPV_CODE CODE="33600000"/></CPV_MAIN></CPV><BLK_BTX><P>Léčivé přípravky a zdravotnické prostředky</P></BLK_BTX></OBJ_NOT><CONTENTS><CORREC><DEL><MIXED>Nedokončené řízení</MIXED><MIXED>Zadávací řízení bylo prohlášeno za neúspěšné</MIXED></DEL></CORREC><P>Další dodatečné informace</P><P>Das Zulassungsverfahren zum Wirkstoff Estramustin, ATC L01XX11 endete zum regulären Ende zum 30.11.2017. Es erfolgte kein Vertragsbeitritt.</P></CONTENTS></FD_OTH_NOT></OTH_NOT><OTH_NOT CATEGORY="TRANSLATION" LG="ET" VERSION="R2.0.8.S03.E01"><FD_OTH_NOT><TI_DOC><P>DE-Hamburg: Ravimid</P></TI_DOC><STI_DOC><P><ADDRESS_NOT_STRUCT><ORGANISATION>DAK-Gesundheit</ORGANISATION><BLK_BTX>, </BLK_BTX><ADDRESS>Nagelsweg 27-31</ADDRESS><BLK_BTX>, Kontaktisik: </BLK_BTX><ATTENTION>Strategischer Einkauf und Vergabestelle II – 0042 60</ATTENTION><BLK_BTX>, </BLK_BTX><TOWN>Hamburg</TOWN><BLK_BTX> </BLK_BTX><POSTAL_CODE>20097</POSTAL_CODE><BLK_BTX>, </BLK_BTX><COUNTRY VALUE="DE"/><BLK_BTX>. Telefon: </BLK_BTX><PHONE>+49 402396-2779</PHONE><BLK_BTX>. Faks: </BLK_BTX><FAX>+49 402396-3661</FAX><BLK_BTX>. E-post: </BLK_BTX><E_MAIL>vergabestelle@dak.de</E_MAIL></ADDRESS_NOT_STRUCT></P></STI_DOC><STI_DOC><P><FT TYPE="REFOJ">(Euroopa Liidu Teataja täiendus, 24.10.2015, 2015/S 207-375270)</FT></P></STI_DOC><OBJ_NOT><INT_OBJ_NOT>Objekt</INT_OBJ_NOT><CPV><CPV_MAIN><CPV_CODE CODE="33600000"/></CPV_MAIN></CPV><BLK_BTX><P>Ravimid</P></BLK_BTX></OBJ_NOT><CONTENTS><CORREC><DEL><MIXED>Lõpetamata protseduur</MIXED><MIXED>Lepingu sõlmimise menetlus on kuulutatud ebaedukaks</MIXED></DEL></CORREC><P>Muu lisateave</P><P>Das Zulassungsverfahren zum Wirkstoff Estramustin, ATC L01XX11 endete zum regulären Ende zum 30.11.2017. Es erfolgte kein Vertragsbeitritt.</P></CONTENTS></FD_OTH_NOT></OTH_NOT><OTH_NOT CATEGORY="TRANSLATION" LG="HU" VERSION="R2.0.8.S03.E01"><FD_OTH_NOT><TI_DOC><P>DE-Hamburg: Gyógyszerészeti termékek</P></TI_DOC><STI_DOC><P><ADDRESS_NOT_STRUCT><ORGANISATION>DAK-Gesundheit</ORGANISATION><BLK_BTX>, </BLK_BTX><ADDRESS>Nagelsweg 27-31</ADDRESS><BLK_BTX>, Címzett: </BLK_BTX><ATTENTION>Strategischer Einkauf und Vergabestelle II – 0042 60</ATTENTION><BLK_BTX>, </BLK_BTX><TOWN>Hamburg</TOWN><BLK_BTX> </BLK_BTX><POSTAL_CODE>20097</POSTAL_CODE><BLK_BTX>, </BLK_BTX><COUNTRY VALUE="DE"/><BLK_BTX>. Telefon: </BLK_BTX><PHONE>+49 402396-2779</PHONE><BLK_BTX>. Fax: </BLK_BTX><FAX>+49 402396-3661</FAX><BLK_BTX>. E-mail: </BLK_BTX><E_MAIL>vergabestelle@dak.de</E_MAIL></ADDRESS_NOT_STRUCT></P></STI_DOC><STI_DOC><P><FT TYPE="REFOJ">(Kiegészítés az Európai Unió Hivatalos Lapjához, 24.10.2015, 2015/S 207-375270)</FT></P></STI_DOC><OBJ_NOT><INT_OBJ_NOT>Tárgy:</INT_OBJ_NOT><CPV><CPV_MAIN><CPV_CODE CODE="33600000"/></CPV_MAIN></CPV><BLK_BTX><P>Gyógyszerészeti termékek</P></BLK_BTX></OBJ_NOT><CONTENTS><CORREC><DEL><MIXED>Befejezetlen eljárás</MIXED><MIXED>A közbeszerzési eljárást eredménytelennek minősítették</MIXED></DEL></CORREC><P>További információk</P><P>Das Zulassungsverfahren zum Wirkstoff Estramustin, ATC L01XX11 endete zum regulären Ende zum 30.11.2017. Es erfolgte kein Vertragsbeitritt.</P></CONTENTS></FD_OTH_NOT></OTH_NOT><OTH_NOT CATEGORY="TRANSLATION" LG="LT" VERSION="R2.0.8.S03.E01"><FD_OTH_NOT><TI_DOC><P>DE-Hamburgas: Farmacijos produktai</P></TI_DOC><STI_DOC><P><ADDRESS_NOT_STRUCT><ORGANISATION>DAK-Gesundheit</ORGANISATION><BLK_BTX>, </BLK_BTX><ADDRESS>Nagelsweg 27-31</ADDRESS><BLK_BTX>, Kam: </BLK_BTX><ATTENTION>Strategischer Einkauf und Vergabestelle II – 0042 60</ATTENTION><BLK_BTX>, </BLK_BTX><TOWN>Hamburg</TOWN><BLK_BTX> </BLK_BTX><POSTAL_CODE>20097</POSTAL_CODE><BLK_BTX>, </BLK_BTX><COUNTRY VALUE="DE"/><BLK_BTX>. Telefonas: </BLK_BTX><PHONE>+49 402396-2779</PHONE><BLK_BTX>. Faksas: </BLK_BTX><FAX>+49 402396-3661</FAX><BLK_BTX>. El. paštas: </BLK_BTX><E_MAIL>vergabestelle@dak.de</E_MAIL></ADDRESS_NOT_STRUCT></P></STI_DOC><STI_DOC><P><FT TYPE="REFOJ">(Europos Bendrijos Oficialiojo Leidinio priedas, 24.10.2015, 2015/S 207-375270)</FT></P></STI_DOC><OBJ_NOT><INT_OBJ_NOT>Objektas</INT_OBJ_NOT><CPV><CPV_MAIN><CPV_CODE CODE="33600000"/></CPV_MAIN></CPV><BLK_BTX><P>Farmacijos produktai</P></BLK_BTX></OBJ_NOT><CONTENTS><CORREC><DEL><MIXED>Nebaigta procedūra</MIXED><MIXED>Paskyrimo procedūra buvo paskelbta nesėkminga</MIXED></DEL></CORREC><P>Kita papildoma informacija</P><P>Das Zulassungsverfahren zum Wirkstoff Estramustin, ATC L01XX11 endete zum regulären Ende zum 30.11.2017. Es erfolgte kein Vertragsbeitritt.</P></CONTENTS></FD_OTH_NOT></OTH_NOT><OTH_NOT CATEGORY="TRANSLATION" LG="LV" VERSION="R2.0.8.S03.E01"><FD_OTH_NOT><TI_DOC><P>DE-Hamburga: Farmācijas izstrādājumi</P></TI_DOC><STI_DOC><P><ADDRESS_NOT_STRUCT><ORGANISATION>DAK-Gesundheit</ORGANISATION><BLK_BTX>, </BLK_BTX><ADDRESS>Nagelsweg 27-31</ADDRESS><BLK_BTX>, Kontaktpersona(-as): </BLK_BTX><ATTENTION>Strategischer Einkauf und Vergabestelle II – 0042 60</ATTENTION><BLK_BTX>, </BLK_BTX><TOWN>Hamburg</TOWN><BLK_BTX> </BLK_BTX><POSTAL_CODE>20097</POSTAL_CODE><BLK_BTX>, </BLK_BTX><COUNTRY VALUE="DE"/><BLK_BTX>. Tālrunis: </BLK_BTX><PHONE>+49 402396-2779</PHONE><BLK_BTX>. Fakss: </BLK_BTX><FAX>+49 402396-3661</FAX><BLK_BTX>. E-pasts: </BLK_BTX><E_MAIL>vergabestelle@dak.de</E_MAIL></ADDRESS_NOT_STRUCT></P></STI_DOC><STI_DOC><P><FT TYPE="REFOJ">(Eiropas Savienības Oficiālā Vēstneša pielikums, 24.10.2015, 2015/S 207-375270)</FT></P></STI_DOC><OBJ_NOT><INT_OBJ_NOT>Priekšmets:</INT_OBJ_NOT><CPV><CPV_MAIN><CPV_CODE CODE="33600000"/></CPV_MAIN></CPV><BLK_BTX><P>Farmācijas izstrādājumi</P></BLK_BTX></OBJ_NOT><CONTENTS><CORREC><DEL><MIXED>Nepilnīga procedūra</MIXED><MIXED>Līguma piešķiršanas procedūra tika izsludināta par neveiksmīgu</MIXED></DEL></CORREC><P>Cita papildu informācija</P><P>Das Zulassungsverfahren zum Wirkstoff Estramustin, ATC L01XX11 endete zum regulären Ende zum 30.11.2017. Es erfolgte kein Vertragsbeitritt.</P></CONTENTS></FD_OTH_NOT></OTH_NOT><OTH_NOT CATEGORY="TRANSLATION" LG="MT" VERSION="R2.0.8.S03.E01"><FD_OTH_NOT><TI_DOC><P>DE-Ħamburgu: Prodotti farmaċewtiċi</P></TI_DOC><STI_DOC><P><ADDRESS_NOT_STRUCT><ORGANISATION>DAK-Gesundheit</ORGANISATION><BLK_BTX>, </BLK_BTX><ADDRESS>Nagelsweg 27-31</ADDRESS><BLK_BTX>, Għall-attenzjoni ta’: </BLK_BTX><ATTENTION>Strategischer Einkauf und Vergabestelle II – 0042 60</ATTENTION><BLK_BTX>, </BLK_BTX><TOWN>Hamburg</TOWN><BLK_BTX> </BLK_BTX><POSTAL_CODE>20097</POSTAL_CODE><BLK_BTX>, </BLK_BTX><COUNTRY VALUE="DE"/><BLK_BTX>. Telefown: </BLK_BTX><PHONE>+49 402396-2779</PHONE><BLK_BTX>. Feks: </BLK_BTX><FAX>+49 402396-3661</FAX><BLK_BTX>. Posta elettronika: </BLK_BTX><E_MAIL>vergabestelle@dak.de</E_MAIL></ADDRESS_NOT_STRUCT></P></STI_DOC><STI_DOC><P><FT TYPE="REFOJ">(Supplement tal-Gurnal Ufficjali ta’ l-Unjoni Ewropea’, 24.10.2015, 2015/S 207-375270)</FT></P></STI_DOC><OBJ_NOT><INT_OBJ_NOT>Oġġett</INT_OBJ_NOT><CPV><CPV_MAIN><CPV_CODE CODE="33600000"/></CPV_MAIN></CPV><BLK_BTX><P>Prodotti farmaċewtiċi</P></BLK_BTX></OBJ_NOT><CONTENTS><CORREC><DEL><MIXED>Proċedura mhux kompluta</MIXED><MIXED>Il-proċedura tal-għoti ma rnexxietx</MIXED></DEL></CORREC><P>Informazzjoni addizzjonali oħra</P><P>Das Zulassungsverfahren zum Wirkstoff Estramustin, ATC L01XX11 endete zum regulären Ende zum 30.11.2017. Es erfolgte kein Vertragsbeitritt.</P></CONTENTS></FD_OTH_NOT></OTH_NOT><OTH_NOT CATEGORY="TRANSLATION" LG="PL" VERSION="R2.0.8.S03.E01"><FD_OTH_NOT><TI_DOC><P>DE-Hamburg: Produkty farmaceutyczne</P></TI_DOC><STI_DOC><P><ADDRESS_NOT_STRUCT><ORGANISATION>DAK-Gesundheit</ORGANISATION><BLK_BTX>, </BLK_BTX><ADDRESS>Nagelsweg 27-31</ADDRESS><BLK_BTX>, Osoba do kontaktów: </BLK_BTX><ATTENTION>Strategischer Einkauf und Vergabestelle II – 0042 60</ATTENTION><BLK_BTX>, </BLK_BTX><TOWN>Hamburg</TOWN><BLK_BTX> </BLK_BTX><POSTAL_CODE>20097</POSTAL_CODE><BLK_BTX>, </BLK_BTX><COUNTRY VALUE="DE"/><BLK_BTX>. Tel.: </BLK_BTX><PHONE>+49 402396-2779</PHONE><BLK_BTX>. Faks: </BLK_BTX><FAX>+49 402396-3661</FAX><BLK_BTX>. E-mail: </BLK_BTX><E_MAIL>vergabestelle@dak.de</E_MAIL></ADDRESS_NOT_STRUCT></P></STI_DOC><STI_DOC><P><FT TYPE="REFOJ">(Suplement do Dziennika Urzędowego Unii Europejskiej, 24.10.2015, 2015/S 207-375270)</FT></P></STI_DOC><OBJ_NOT><INT_OBJ_NOT>Przedmiot zamówienia:</INT_OBJ_NOT><CPV><CPV_MAIN><CPV_CODE CODE="33600000"/></CPV_MAIN></CPV><BLK_BTX><P>Produkty farmaceutyczne</P></BLK_BTX></OBJ_NOT><CONTENTS><CORREC><DEL><MIXED>Procedury niepełnej</MIXED><MIXED>Postępowanie o udzielenie zamówienia uznano za nieskuteczne</MIXED></DEL></CORREC><P>Inne dodatkowe informacje</P><P>Das Zulassungsverfahren zum Wirkstoff Estramustin, ATC L01XX11 endete zum regulären Ende zum 30.11.2017. Es erfolgte kein Vertragsbeitritt.</P></CONTENTS></FD_OTH_NOT></OTH_NOT><OTH_NOT CATEGORY="TRANSLATION" LG="SK" VERSION="R2.0.8.S03.E01"><FD_OTH_NOT><TI_DOC><P>DE-Hamburg: Farmaceutické výrobky</P></TI_DOC><STI_DOC><P><ADDRESS_NOT_STRUCT><ORGANISATION>DAK-Gesundheit</ORGANISATION><BLK_BTX>, </BLK_BTX><ADDRESS>Nagelsweg 27-31</ADDRESS><BLK_BTX>, Kontaktná osoba: </BLK_BTX><ATTENTION>Strategischer Einkauf und Vergabestelle II – 0042 60</ATTENTION><BLK_BTX>, </BLK_BTX><TOWN>Hamburg</TOWN><BLK_BTX> </BLK_BTX><POSTAL_CODE>20097</POSTAL_CODE><BLK_BTX>, </BLK_BTX><COUNTRY VALUE="DE"/><BLK_BTX>. Telefón: </BLK_BTX><PHONE>+49 402396-2779</PHONE><BLK_BTX>. Fax: </BLK_BTX><FAX>+49 402396-3661</FAX><BLK_BTX>. E-mail: </BLK_BTX><E_MAIL>vergabestelle@dak.de</E_MAIL></ADDRESS_NOT_STRUCT></P></STI_DOC><STI_DOC><P><FT TYPE="REFOJ">(Príloha k Úradnému vestníku Európskej únie, 24.10.2015, 2015/S 207-375270)</FT></P></STI_DOC><OBJ_NOT><INT_OBJ_NOT>Predmet:</INT_OBJ_NOT><CPV><CPV_MAIN><CPV_CODE CODE="33600000"/></CPV_MAIN></CPV><BLK_BTX><P>Farmaceutické výrobky</P></BLK_BTX></OBJ_NOT><CONTENTS><CORREC><DEL><MIXED>Neukončené konanie</MIXED><MIXED>Postup pridelenia obstarávania bol vyhlásený za neúspešný</MIXED></DEL></CORREC><P>Ďalšie dodatočné informácie</P><P>Das Zulassungsverfahren zum Wirkstoff Estramustin, ATC L01XX11 endete zum regulären Ende zum 30.11.2017. Es erfolgte kein Vertragsbeitritt.</P></CONTENTS></FD_OTH_NOT></OTH_NOT><OTH_NOT CATEGORY="TRANSLATION" LG="SL" VERSION="R2.0.8.S03.E01"><FD_OTH_NOT><TI_DOC><P>DE-Hamburg: Farmacevtski proizvodi</P></TI_DOC><STI_DOC><P><ADDRESS_NOT_STRUCT><ORGANISATION>DAK-Gesundheit</ORGANISATION><BLK_BTX>, </BLK_BTX><ADDRESS>Nagelsweg 27-31</ADDRESS><BLK_BTX>, V roke: </BLK_BTX><ATTENTION>Strategischer Einkauf und Vergabestelle II – 0042 60</ATTENTION><BLK_BTX>, </BLK_BTX><TOWN>Hamburg</TOWN><BLK_BTX> </BLK_BTX><POSTAL_CODE>20097</POSTAL_CODE><BLK_BTX>, </BLK_BTX><COUNTRY VALUE="DE"/><BLK_BTX>. Telefon: </BLK_BTX><PHONE>+49 402396-2779</PHONE><BLK_BTX>. Telefaks: </BLK_BTX><FAX>+49 402396-3661</FAX><BLK_BTX>. E-pošta: </BLK_BTX><E_MAIL>vergabestelle@dak.de</E_MAIL></ADDRESS_NOT_STRUCT></P></STI_DOC><STI_DOC><P><FT TYPE="REFOJ">(Dodatek k Uradnemu listu Evropske unije, 24.10.2015, 2015/S 207-375270)</FT></P></STI_DOC><OBJ_NOT><INT_OBJ_NOT>Predmet:</INT_OBJ_NOT><CPV><CPV_MAIN><CPV_CODE CODE="33600000"/></CPV_MAIN></CPV><BLK_BTX><P>Farmacevtski proizvodi</P></BLK_BTX></OBJ_NOT><CONTENTS><CORREC><DEL><MIXED>Nedokončani postopek</MIXED><MIXED>Postopek dodelitve je bil razglašen za neuspešnega</MIXED></DEL></CORREC><P>Druge dodatne informacije</P><P>Das Zulassungsverfahren zum Wirkstoff Estramustin, ATC L01XX11 endete zum regulären Ende zum 30.11.2017. Es erfolgte kein Vertragsbeitritt.</P></CONTENTS></FD_OTH_NOT></OTH_NOT><OTH_NOT CATEGORY="TRANSLATION" LG="GA" VERSION="R2.0.8.S03.E01"><FD_OTH_NOT><TI_DOC><P>DE-Hamburg: Pharmaceutical products</P></TI_DOC><STI_DOC><P><ADDRESS_NOT_STRUCT><ORGANISATION>DAK-Gesundheit</ORGANISATION><BLK_BTX>, </BLK_BTX><ADDRESS>Nagelsweg 27-31</ADDRESS><BLK_BTX>, Le cur faoi bhráid: </BLK_BTX><ATTENTION>Strategischer Einkauf und Vergabestelle II – 0042 60</ATTENTION><BLK_BTX>, </BLK_BTX><TOWN>Hamburg</TOWN><BLK_BTX> </BLK_BTX><POSTAL_CODE>20097</POSTAL_CODE><BLK_BTX>, </BLK_BTX><COUNTRY VALUE="DE"/><BLK_BTX>. Teileafón: </BLK_BTX><PHONE>+49 402396-2779</PHONE><BLK_BTX>. Facs: </BLK_BTX><FAX>+49 402396-3661</FAX><BLK_BTX>. Ríomhphost: </BLK_BTX><E_MAIL>vergabestelle@dak.de</E_MAIL></ADDRESS_NOT_STRUCT></P></STI_DOC><STI_DOC><P><FT TYPE="REFOJ">(Forlíonaidh d'Iris Oifigiúil an Aontais Eorpaigh, 24.10.2015, 2015/S 207-375270)</FT></P></STI_DOC><OBJ_NOT><INT_OBJ_NOT>MAIDIR LE:</INT_OBJ_NOT><CPV><CPV_MAIN><CPV_CODE CODE="33600000"/></CPV_MAIN></CPV><BLK_BTX><P>Pharmaceutical products</P></BLK_BTX></OBJ_NOT><CONTENTS><CORREC><DEL><MIXED>Nós imeachta neamhiomlán</MIXED><MIXED>Fógraíodh nár éirigh leis an nós imeachta dámhachtana</MIXED></DEL></CORREC><P>Faisnéis bhreise eile</P><P>Das Zulassungsverfahren zum Wirkstoff Estramustin, ATC L01XX11 endete zum regulären Ende zum 30.11.2017. Es erfolgte kein Vertragsbeitritt.</P></CONTENTS></FD_OTH_NOT></OTH_NOT><OTH_NOT CATEGORY="TRANSLATION" LG="BG" VERSION="R2.0.8.S03.E01"><FD_OTH_NOT><TI_DOC><P>DE-Хамбург: Фармацевтични продукти</P></TI_DOC><STI_DOC><P><ADDRESS_NOT_STRUCT><ORGANISATION>DAK-Gesundheit</ORGANISATION><BLK_BTX>, </BLK_BTX><ADDRESS>Nagelsweg 27-31</ADDRESS><BLK_BTX>, На вниманието на: </BLK_BTX><ATTENTION>Strategischer Einkauf und Vergabestelle II – 0042 60</ATTENTION><BLK_BTX>, </BLK_BTX><TOWN>Hamburg</TOWN><BLK_BTX> </BLK_BTX><POSTAL_CODE>20097</POSTAL_CODE><BLK_BTX>, </BLK_BTX><COUNTRY VALUE="DE"/><BLK_BTX>. Телефон: </BLK_BTX><PHONE>+49 402396-2779</PHONE><BLK_BTX>. Факс: </BLK_BTX><FAX>+49 402396-3661</FAX><BLK_BTX>. Адрес за електронна поща: </BLK_BTX><E_MAIL>vergabestelle@dak.de</E_MAIL></ADDRESS_NOT_STRUCT></P></STI_DOC><STI_DOC><P><FT TYPE="REFOJ">(Приложение към Официален вестник на Европейския съюз, 24.10.2015, 2015/S 207-375270)</FT></P></STI_DOC><OBJ_NOT><INT_OBJ_NOT>Относно:</INT_OBJ_NOT><CPV><CPV_MAIN><CPV_CODE CODE="33600000"/></CPV_MAIN></CPV><BLK_BTX><P>Фармацевтични продукти</P></BLK_BTX></OBJ_NOT><CONTENTS><CORREC><DEL><MIXED>Незавършена процедура</MIXED><MIXED>Процедурата по възлагане беше обявена за неуспешна</MIXED></DEL></CORREC><P>Друга допълнителна информация</P><P>Das Zulassungsverfahren zum Wirkstoff Estramustin, ATC L01XX11 endete zum regulären Ende zum 30.11.2017. Es erfolgte kein Vertragsbeitritt.</P></CONTENTS></FD_OTH_NOT></OTH_NOT><OTH_NOT CATEGORY="TRANSLATION" LG="RO" VERSION="R2.0.8.S03.E01"><FD_OTH_NOT><TI_DOC><P>DE-Hamburg: Produse farmaceutice</P></TI_DOC><STI_DOC><P><ADDRESS_NOT_STRUCT><ORGANISATION>DAK-Gesundheit</ORGANISATION><BLK_BTX>, </BLK_BTX><ADDRESS>Nagelsweg 27-31</ADDRESS><BLK_BTX>, În atenția: </BLK_BTX><ATTENTION>Strategischer Einkauf und Vergabestelle II – 0042 60</ATTENTION><BLK_BTX>, </BLK_BTX><TOWN>Hamburg</TOWN><BLK_BTX> </BLK_BTX><POSTAL_CODE>20097</POSTAL_CODE><BLK_BTX>, </BLK_BTX><COUNTRY VALUE="DE"/><BLK_BTX>. Telefon: </BLK_BTX><PHONE>+49 402396-2779</PHONE><BLK_BTX>. Fax: </BLK_BTX><FAX>+49 402396-3661</FAX><BLK_BTX>. E-mail: </BLK_BTX><E_MAIL>vergabestelle@dak.de</E_MAIL></ADDRESS_NOT_STRUCT></P></STI_DOC><STI_DOC><P><FT TYPE="REFOJ">(Suplimentul Jurnalului Oficial al Uniunii Europene, 24.10.2015, 2015/S 207-375270)</FT></P></STI_DOC><OBJ_NOT><INT_OBJ_NOT>În ceea ce priveşte:</INT_OBJ_NOT><CPV><CPV_MAIN><CPV_CODE CODE="33600000"/></CPV_MAIN></CPV><BLK_BTX><P>Produse farmaceutice</P></BLK_BTX></OBJ_NOT><CONTENTS><CORREC><DEL><MIXED>Procedură incompletă</MIXED><MIXED>Procedura de atribuire a fost declarată nereușită</MIXED></DEL></CORREC><P>Alte informații suplimentare</P><P>Das Zulassungsverfahren zum Wirkstoff Estramustin, ATC L01XX11 endete zum regulären Ende zum 30.11.2017. Es erfolgte kein Vertragsbeitritt.</P></CONTENTS></FD_OTH_NOT></OTH_NOT><OTH_NOT CATEGORY="TRANSLATION" LG="HR" VERSION="R2.0.8.S03.E01"><FD_OTH_NOT><TI_DOC><P>DE-Hamburg: Farmaceutski proizvodi</P></TI_DOC><STI_DOC><P><ADDRESS_NOT_STRUCT><ORGANISATION>DAK-Gesundheit</ORGANISATION><BLK_BTX>, </BLK_BTX><ADDRESS>Nagelsweg 27-31</ADDRESS><BLK_BTX>, Na pažnju (osoba za kontakt): </BLK_BTX><ATTENTION>Strategischer Einkauf und Vergabestelle II – 0042 60</ATTENTION><BLK_BTX>, </BLK_BTX><TOWN>Hamburg</TOWN><BLK_BTX> </BLK_BTX><POSTAL_CODE>20097</POSTAL_CODE><BLK_BTX>, </BLK_BTX><COUNTRY VALUE="DE"/><BLK_BTX>. Telefon: </BLK_BTX><PHONE>+49 402396-2779</PHONE><BLK_BTX>. Telefaks: </BLK_BTX><FAX>+49 402396-3661</FAX><BLK_BTX>. E-pošta: </BLK_BTX><E_MAIL>vergabestelle@dak.de</E_MAIL></ADDRESS_NOT_STRUCT></P></STI_DOC><STI_DOC><P><FT TYPE="REFOJ">(Dodatak Službenom listu Europske unije, 24.10.2015, 2015/S 207-375270)</FT></P></STI_DOC><OBJ_NOT><INT_OBJ_NOT>Predmet:</INT_OBJ_NOT><CPV><CPV_MAIN><CPV_CODE CODE="33600000"/></CPV_MAIN></CPV><BLK_BTX><P>Farmaceutski proizvodi</P></BLK_BTX></OBJ_NOT><CONTENTS><CORREC><DEL><MIXED>Poništenje postupka</MIXED><MIXED>Postupak javne nabave je poništen</MIXED></DEL></CORREC><P>Ostali dodatni podaci</P><P>Das Zulassungsverfahren zum Wirkstoff Estramustin, ATC L01XX11 endete zum regulären Ende zum 30.11.2017. Es erfolgte kein Vertragsbeitritt.</P></CONTENTS></FD_OTH_NOT></OTH_NOT></FORM_SECTION></TED_EXPORT>